Heart Test Laboratories announces Canada patent grant covering MyoVista

Heart Test Laboratories announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian Intellectual Property Office. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of conventional ECG’s are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs. We are pleased to receive this latest patent grant in Canada. Over recent years we have conscientiously built an extensive international intellectual property portfolio across major markets which we expect will provide competitive advantage and intrinsic corporate value as AI is set to drive significant growth in the ECG market to $25 billion per year by 2032.”